Patients with cancer frequently suffer from concurrent chronic kidney disease (CKD), with a prevalence ranging from 12%-53% at cancer diagnosis. Eighty-five percent of drug trials for the 5 most common malignancies published in high–impact factor journals excluded most patients with CKD.¹ Of note, serum creatinine thresholds were the exclusion criteria in 62% of patients.¹ CKD is common in patients with cancer, which excludes these patients from clinical trials, limiting their access to therapies that could potentially improve their outcomes and to information on adverse drug affects. The IRMA study found that potentially nephrotoxic drugs were used in 80.1% of chemotherapy sessions, with dose adjustment based on kidney function required in 79.9%.² Because dose adjustments of chemotherapeutics are fundamental in the treatment of patients with cancer, kidney function must be measured accurately to avoid both underdosing and overdosing. These two issues must be considered by clinical oncology trialists and addressed in future cancer trials.

中文翻译：

---

改善慢性肾脏病患者的癌症护理。

癌症患者经常患有并发的慢性​​肾脏疾病（CKD），在癌症诊断中的患病率范围为12％-53％。在高影响因子期刊上发表的有关5种最常见恶性肿瘤的药物试验中，有85％排除了大多数CKD患者。¹值得注意的是，血清肌酐阈值是62％患者的排除标准。¹ CKD在癌症患者中很常见，这将这些患者排除在临床试验之外，从而限制了他们获得可能改善其治疗效果的疗法以及获得有关药物不良影响的信息的机会。IRMA研究发现，在80.1％的化疗疗程中使用了潜在的肾毒性药物，其中79.9％的患者根据肾功能进行剂量调整。^2个由于化学治疗剂的剂量调整对于癌症患者的治疗至关重要，因此必须准确测量肾脏功能，以避免剂量不足和剂量过量。临床肿瘤学专家必须考虑这两个问题，并在以后的癌症试验中加以解决。